C.H.TDR.NEMATIPOUR. C.H.T DR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE DR EBRAHIM NEMATIPOUR CARDIOLOGIST AND PROFESSOR.

Slides:



Advertisements
Similar presentations
Ionotropic Therapy in Acute Heart Failure
Advertisements

Exercise Stress Electrocardiography
 Cardiovascular System – Heart and Blood Vessels Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Ryan Hampton January  Risks and benefits of surgery  Timing of surgery  Type of Surgery  Goal is to uncover undiagnosed problems or treat prior.
Drugs to treat angina. I. Introduction Branching off the aorta are the coronary arteries.
Ischemic Heart Disease.  Coronary artery disease CAD is a general manifestation that dose not discriminate bet the various phases that the individual.
ACSM’s Guidelines For Exercise Testing And Prescription : Chapter 2 Health Screening & Risk Stratification David Arnall, Ph.D., P.T., FACSM, ES.
CORONARY CIRCULATION DR. Eman El Eter.
Diseases of the Cardiovascular System Ischemic Heart Disease – Myocardial Infartcion – Sudden Cardiac Death – Heart Failure – Stroke + A Tiny Bit on the.
CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O..
Ischemic Heart Diseases IHD
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Angina and MI.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
1 Covenants of the Medical Home Neighborhood  How Primary Care Physicians and Specialists can “Choose Wisely”
Drugs for Hypertension
Stroke Awareness & Prevention Suheb Hasan, MD Health Seminar MCWS November 17, 2012.
20 Cardiovascular Disease and Physical Activity chapter.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
Dr. Mehdi Reza Emadzadeh Department of cardiology Mashhad University of Medical Science.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
Gilead -Topics in Human Pathophysiology Fall 2010 Drug Safety and Public Health.
© Continuing Medical Implementation ® …...bridging the care gap Cardiovascular Aging.
Cardiac Rehabilitation Presented By: Dr. Ramesh Tharwani Consultant Cardiologist Choithram Hospital.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
CORONARY CIRCULATION DR. Eman El Eter. Coronary Arteries The major vessels of the coronary circulation are: 1- left main coronary that divides into left.
Dr Jayachandran Thejus.  Coronary artery disease-  Block in coronary artery due to plaque or thrombus  Leads to myocardial ischemia manifested as chest.
CARDIOVASCULAR MODULE: HYPERTENSION Adult Medical-Surgical Nursing.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Cardio Investigations. Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. Risk Factor.
3/99medslides.com1 Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery ACC/AHA Task Force JACC 1996; 27: Circulation 1996;
Agents that Dilate Coronary Blood Vessels.  Coronary artery disease (CAD) results from atherosclerosis  Clinical symptoms caused by  narrowing of the.
Heart failure Dr Rafat Mosalli. Objectives Definition Definition Pathophysiology Pathophysiology Age specific Causes Age specific Causes Clinical pictures.
Nursing and heart failure
Nancy Houston-Miller RN
Drugs Affecting Blood Pressure Brenda B. Rowe. Vasopressors Treat shock Treat shock Dopamine (Intropin) – stimulates alpha-1 & beta-1 Dopamine (Intropin)
Pre-operative Cardiovascular Evaluation: Guidelines and More Eric A. Brody MD, FACC Medical Director, NA Cardiology and Medical Services Associate Professor.
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm. Due to imbalance between myocardium oxygen requirement and.
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
Dr. Sohail Bashir Sulehria
Internal Medicine Workshop Series Laos September /October 2009
Angina pectoris Sudden,severe,pressing chest pain starting substernal &radiate to left arm & neck. Due to imbalance between myocardium oxygen requirement.
Michelle Gardner RN NUR-224. OBJECTIVES  Define normal blood pressure and categories of abnormal pressure  Identify risk factors for hypertension 
Heart Failure  Dfinition:  Clinical features  Underlying causes of HF include Arteriosclerotic heart disease, MI, hypertensive heart disease, valvular.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Indication Contraindication Preparation
Adie Viljoen Lister Hospital
Cardiac Rehabilitation Part I
Drugs for Hypertension
CORONARY ARTERY DISEASE
Sildenafil detected significant coronary artery stenosis
Cardiac rehabilitation phase II
Drugs Affecting the Cardiovascular System
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Erectile Dysfunction Treatment and causes (Tadaga)
About Tadapox Effective in treating Erectile Dysfunction (ED) and Premature Ejaculation (PE). Contains 20 mg Tadalafil and 60 mg Dapoxetine. Clinically.
Hypertension (High Blood Pressure)
Volume 70, Issue 2, Pages (August 2016)
Section I: Clinical and epidemiological correlates of erectile dysfunction and cardiovascular disease Prevalence of sexual dysfunction in US adults Content.
Section V: Erectile dysfunction: The patients you see
Section III: Neurohormonal strategies in heart failure
Antianginal Drugs.
THE ELDERLY POPULATION
Recent advances – levosimendan
Drugs Affecting Blood Pressure
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Presentation transcript:

C.H.TDR.NEMATIPOUR

C.H.T DR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE DR EBRAHIM NEMATIPOUR CARDIOLOGIST AND PROFESSOR OF TEHRAN CARDIOLOGIST AND PROFESSOR OF TEHRAN UNIVERSITY OF MEDICAL SCIENCES UNIVERSITY OF MEDICAL SCIENCES

C.H.TDR.NEMATIPOUR * Risk of myocardial infarction (MI) after sex * Sexual activity in patients with heart disease. * Sexual dysfunction in patients with heart disease * Treatment of sexual dysfunction in patients with heart disease SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE SUBJECTS

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE * Sexual function is an important component of quality of life and subjective well- being * Unfortunately many physicians do not discuss this issue with their patients * Patients seeking medical attention for sexual dysfunction often have concomitant cardiovascular disease * Prevalence of erectile dysfunction in CAD patients ranged from 42% to75%

C.H.TDR.NEMATIPOUR Pathophysiology of erectile function (1) Normal sexual function : symphony of simultaneous interplay between psychologic, hormonal, vascular, and neurologic factors Vascular phenomenon SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE Sexual arousal and erection in men : Parasympathetic nerves stimulation, sympathetic pathways activity reduction, release of nitric oxide from endothelium. ( In women result from sympathetic nervous system activation).

C.H.TDR.NEMATIPOUR Smooth muscle relaxation in vascular chambers by nitric oxide ( NO ) NO stimulate adenylate cyclase intracellular cyclic guanosine monophosphate ( cGMP ) and cAMP erectile smooth muscle relaxation. 5 cGMP phosphodiestrase revokes vasodilatory effects. PDE-5 inhibitors prolong the vasodilation Pathophysiology of erectile function (2) SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE RISK OF MYOCARDIAL INFARCTION (MI) AFTER SEX * Maximum relative risk of MI(2.5) is with in 2 hours after sexual activity. * Absolute increase in risk is small ( contribute to the onset of MI in less than 1 percent of patients ) * Many other trigger of MI ( Psychologic stress, anger, physical activity ) may cause a greater increase in absolute risk because they occur more frequently

C.H.TDR.NEMATIPOUR - Mean heart rate : ~ 120 beats per minute - Mean blood pressure : ~ 160/ to 4 MET (during orgasm ) 1 MET (metabolic equivalent of oxygen consumption ) : 3.5 ml o 2 uptake /Kg per min - Walking at 2 to 4 miles ( ~ 3.2 to 6.4 Km ) per hour on a level Surface - Brisk walk up to two flights of stairs ( ~ 5 MET ) * Modest increase in myocardial oxygen demand that lasts only a brief time SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE Hemodynamic stress of normal sexual activity

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY IN PATIENTS WITH HEART DISEASE (1) * Risk assessment befere initiation or resumption of sexual activity : - Low risk - Intermediate or indeterminate risk - High risk SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY IN PATIENTS WITH HEART DISEASE (2) SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE Low risk patients : - No symptoms and less than three cardiovascular risk factors ( excluding gender ) - Controlled hypertension - Mild, stable angina - Successful coronary revascularization

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE - MI more than 6 to 8 weeks previously in asymptomatic patients and no exercise-induced ischemia, or revascularized - (probably safe 3 to 4 weeks post MI in revasularized and without exercise-induced ischemia ) - Mild valvular disease * Patients at low risk can be safely encouraged to initiate or resume sexual activity and can be treated for sexual dysfunction

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE SEXUAL ACTIVITY IN PATIENTS WITH HEART DISEASE (3) Intermediate or indeterminate risk patients: - No symptoms and 3 or more cardiovascular risk factors (excluding gender) sedentary lifestyle is a risk factor - Moderate, stable angina - Recent MI ( more than 2 and less than 6 weeks )

C.H.TDR.NEMATIPOUR - Non cardiac manifestations of atherosclerotic disease (peripheral vascular disease or prior stroke or TIA ) * Patients in this group should receive further evaluation, such as stress testing, to restratification into low or high risk category SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE Asymptomatic LV dysfunctions ( LVEF < 40% or NYHA class II HF ) - Asymptomatic LV dysfunctions ( LVEF < 40% or NYHA class II HF )

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE SEXUAL ACTIVITY IN PATIENTS WITH HEART DISEASE (4) High risk patients : -Unstable or refractory angina - Uncontrolled hypertension - NYHA class III or IV heart failure -MI within the past 2 Weeks - High-risk arrhythmia - Obstructive hypertrophic cardiomyopathy -Moderate-to-severe valvular disease, particularly aortic stenosis * Patients at high risk should be stabilized by appropriate therapy and further risk stratified before resuming sexual activity

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE (1) SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE (1) sexual dysfunction is common in patients with cardiovascular disease because of: - Concern about risk - Side effects of medications: -Beta- blockers : ill defined mechanism - Lipid lowering drugs : ( ? ) - Digoxin : sodium-pump inhibition corporeal contraction and impaired NO-induced relaxation. - Spironolacton : androgen suppression ? aplerenone ( more selective )

C.H.TDR.NEMATIPOUR -Coexistence of shared risk factors (lipid abnormalities, diabetes, smoking, hypertension) -presence of psychologic factors sexual dysfunction after MI ( most often erectile dysfunction in men) is estimated to occur in one-half to three-quarters of patients. * sexual dysfunction after MI ( most often erectile dysfunction in men) is estimated to occur in one-half to three-quarters of patients. SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE (2) SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE MODULATION OF RISK AND TREATMENT OF SEXUAL DYSFUNCTION IN PATIENT WITH HEART DISEASE ( 1 ) Factors to modulate the risk of MI after intercourse: - Exercise : regular exercise, at levels of ≥ 6 MET s (increases aerobic capacity, decreases peack HR) more regular exercise lower relative risk of MI Attendance at cardiac rehabilitation - Medical therapy: Medication that reduce HR or BP

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE MODULATION OF RISK AND TREATMENT OF SEXUAL DYSFUNCTION IN PATIENT WITH HEART DISEASE (2) Treatment of sexual dysfunction: - Correction of reversible causes: * concern about risk: Reassurance in patients in whom sexual activity is safe * drug induced side effects: alternative prescriptions, when possible - Treatment of erectile dysfunction: Phosphodiesterase-5(PDE-5) inhibitors - sildenafil - vardenafil - tadalafil * PDE-5 inhibitors should not be used with nitrates in any form 24 h of sildenafil and vardenafil and 48 h of tadalafil ( even longer in patients with renal or hepatic dysfunction )

C.H.TDR.NEMATIPOUR The ACC/AHA consensus statement about the groups of patients at risk of potentially hazardous cardiovascular effects of PDE-5 inhibitors. - Patients with active coronary ischemia, even who are not taking nitrate ( positive ETT ) - Patients with HF and borderline low BP and /or low volume status. - patients on a complicated multidrug antihypertensive drugs regimen. - Patients taking drugs that prolong the half – life of PDE – 5 inhibitors by blocking CYP 3A4 SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE

C.H.TDR.NEMATIPOUR SEXUAL ACTIVITY AND SEXUAL DYSFUNCTION IN PATIENTS WITH HEART DISEASE SUMMERY AND CONCLUSION - sexual activity is an important component of quality of life and physicians should discuss this issue with their patients - patients seeking medical attention for sexual dysfunction often have concomitant cardiovascular disease - Absolute increase in risk of MI after sex is small and is less than other triggers of MI - Risk assessment of cardiac patients is necessary before resumption of sexual activity - sexual dysfunction is common in patients with heart disease - The important component of treatment of sexual dysfunction is correction of reversible causes - PED-5 inhibitors can improve erectile function in cardiac patients but should never be used concomitantly with any forms of initrates

C.H.TDR.NEMATIPOUR